Min-Jung Lee

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Fatima Karzai, David James VanderWeele, Ravi A. Madan et al. · Journal for ImmunoTherapy of Cancer · 2018 · 295 citations · Full text

Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial

Anish Thomas, Arun Rajan, Arlene Berman et al. · The Lancet Oncology · 2015 · 293 citations · Full text

Open-label Phase 2, Oncology, Clinical Trials +6

Fumarate Hydratase Deficiency in Renal Cancer Induces Glycolytic Addiction and Hypoxia-Inducible Transcription Factor 1α Stabilization by Glucose-Dependent Generation of Reactive Oxygen Species

Sunil Sudarshan, Carole Sourbier, Hye-Sik Kong et al. · Molecular and Cellular Biology · 2009 · 220 citations · Full text

Metabolic Remodeling, Reactive Oxygen Species, Redox Biology +22

Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors

Giuseppe Giaccone, Arun Rajan, Arlene Berman et al. · Journal of Clinical Oncology · 2011 · 186 citations · Full text

Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer

Yang-Min Ning, James L. Gulley, Philip M. Arlen et al. · Journal of Clinical Oncology · 2010 · 145 citations · Full text

Urology, Oncology, Phase Ii Trial +12